Related Experiment Video

Updated: Jun 7, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.5K

Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance

Ting Mei1,2, Ting Ye1,3, Dingkun Huang1,4

  • 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Cellular Oncology (Dordrecht, Netherlands)
|November 20, 2024
PubMed

Insights

Immunotherapy resistance in cancer can be overcome by inducing immunogenic cell death (ICD) using nanoparticles (NPs). NPs deliver ICD-inducing agents to enhance antitumor immunity and improve immunotherapy efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology

Background:

  • Immunotherapy resistance is a major obstacle in cancer treatment.
  • Immunogenic cell death (ICD) releases tumor antigens, stimulating immune responses.
  • Nanoparticles (NPs) can deliver therapeutic agents and modulate the immune system.

Purpose of the Study:

  • To review mechanisms of immunotherapy resistance.
  • To examine the role of ICD in overcoming resistance.
  • To explore the application of NPs in cancer immunotherapy.

Main Methods:

  • Literature review on immunotherapy resistance.
  • Analysis of ICD pathways (necroptosis, pyroptosis, ferroptosis).
  • Overview of NP-based strategies for ICD induction and immune stimulation.

Main Results:

  • ICD triggers release of tumor antigens and immune-activating molecules.
  • NPs enhance delivery of ICD inducers and adjuvants.
  • NPs can augment anti-tumor immunity and immunotherapy effectiveness.

Conclusions:

  • Nanoparticles offer a promising strategy to induce ICD and enhance cancer immunotherapy.
  • Combining NPs with immunotherapy holds potential to revolutionize cancer treatment.
  • Further research into NP-mediated ICD is crucial for clinical translation.
Keywords:
ICDImmunotherapy resistanceNanoparticlesNanotechnologyTumor

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

697
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K